Navigation Links
Spherix Announces Closing of Registered Direct Offering of $2.77 Million in Common Stock and Warrants
Date:1/24/2011

BETHESDA, Md., Jan. 24, 2011 /PRNewswire/ -- Spherix Incorporated (Nasdaq: SPEX), an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis; and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced the closing of previously reported agreements to sell $2.77 million of shares of its common stock and warrants to purchase shares of its common stock in a registered direct offering to institutional investors.  Spherix has issued an aggregate of 4,269,000 shares of common stock to the institutional investors together with warrants to purchase an additional 2,134,500 shares of common stock. The warrants have an exercise price of $0.80 per share, and are exercisable six months after issuance and terminate 60 months after the date of issuance.

The Company intends to use the net proceeds of approximately $2.6 million from the offering to continue the development of D-tagatose for diabetes and triglycerides, as well as for general corporate purposes.

"We are pleased to have effected this transaction, which will be helpful in funding our initial studies to investigate D-tagatose as a treatment for high triglycerides," commented Dr. Claire L. Kruger, Chief Executive Officer of Spherix. "In addition, these funds will provide us with additional runway as we seek a partner for the further development of the use of D-tagatose in the treatment of diabetes," Dr. Kruger added.

Rodman & Renshaw, LLC, a wholly-owned subsidiary of Rodman & Renshaw Capital Group, Inc., acted as the exclusive placement agent for the offering.

The common stock and warrants are being offered by Spherix pursuant to an effective registration statement on Form S-3 filed with the Securities and Exchange Commission (SEC). A prospectus supplement relating to the of
'/>"/>

SOURCE Spherix Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Spherix Receives Nasdaq Letter Extending Minimum Bid Price Compliance Period
2. Spherix Transfers Stock Listing to Nasdaq Capital Market
3. Spherix Reports 3rd Quarter Earnings
4. Spherix Announces 2008 Financial Results
5. Spherix Recruiting New Independent Director to Regain NASDAQ Compliance
6. Spherix Incorporated Announces the Death of A. Paul Cox, Jr., Chairman of the Board
7. Spherix to Exhibit at the BIO 2009 International Convention
8. Spherix Regains Full NASDAQ Compliance
9. Spherix Announces Full-Scale Production of Pharmaceutical Tagatose
10. Spherix Announces Termination of Arla License Agreement
11. Spherix Reports Second Quarter 2009 Earnings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... CAMBRIDGE, Mass. , July 14, 2014 ... in the development of new therapies to treat neuropsychiatric ... Ahlholm has been appointed vice president of finance ... Mr. Ahlholm is a senior executive with more ... functions at technology and life science companies. His background ...
(Date:7/12/2014)... York (PRWEB) July 12, 2014 ... for various reagents used in the life ... driving the life science reagents market towards ... include manufacturers and providers of life science ... Market Report: http://www.transparencymarketresearch.com/life-sciences-reagents-analytical-reagents.html . , The ...
(Date:7/11/2014)... BCC Research ( http://www.bccresearch.com ) reveals ... REACTION (PCR) TECHNOLOGY: GLOBAL MARKETS , the global market ... $140 billion in 2013. This is estimated to grow ... annual growth rate (CAGR) of 28.6%. , New digital ... exciting possibilities within the broader PCR field. The opportunities ...
(Date:7/11/2014)... 2014 Cayenne Medical, Inc., a ... the soft tissue reconstruction segment, announced the worldwide ... surgeries involving the shoulder and extremities. The SureLock ... inserter-controlled deployment method. The unique delivery eliminates manual ... pull-out, or anchor displacement (also commonly know as ...
Breaking Biology Technology:Minerva Neurosciences Announces Appointment Of Frederick W. Ahlholm As VP Of Finance And Chief Accounting Officer 2Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 2Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 3Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3
... Diagnostics, a leading developer of biofluid-based molecular diagnostic ... the appointment of David Okrongly, Ph.D., as chief ... medical officer, and Sally Bowden, Ph.D., as director ... of cardiothoracic surgery Harvard University and Michael Manyak, ...
... Glioblastoma is one of the most aggressive forms ... tumor, glioblastoma will often infiltrate the surrounding brain tissue, ... chemotherapy or radiation. Likewise, several mouse models of glioblastoma ... a new study, a team led by scientists at ...
... announced today the launch of Curve™ Image Guided Surgery. ... surgery, is unveiling at the Congress of Neurological Surgeons ... of enhancements based on years of feedback from our ... for Brainlab and has helped to produce the ultimate ...
Cached Biology Technology:Exosome Diagnostics Announces Additions to Management and Scientific Advisory Board as Company Expands Clinical Validation Studies in Oncology 2Exosome Diagnostics Announces Additions to Management and Scientific Advisory Board as Company Expands Clinical Validation Studies in Oncology 3Exosome Diagnostics Announces Additions to Management and Scientific Advisory Board as Company Expands Clinical Validation Studies in Oncology 4Exosome Diagnostics Announces Additions to Management and Scientific Advisory Board as Company Expands Clinical Validation Studies in Oncology 5Nanoparticles seek and destroy glioblastoma in mice 2Nanoparticles seek and destroy glioblastoma in mice 3Brainlab Launches Newest Innovation in Image Guided Surgery Technology 2Brainlab Launches Newest Innovation in Image Guided Surgery Technology 3
(Date:7/13/2014)... more effective treatments for cachexia, a profound wasting of ... cancer patients, raising their risk of death, according to ... been tried to reverse the condition, which may cause ... but none have had great success. , Scientists reporting ... Nature , led by Bruce Spiegelman, PhD, demonstrated that ...
(Date:7/11/2014)... the City of Entiat on Tuesday, July 8, 2014. ... grew to over 1,000 acres by evening. Three outbuildings ... investigation by the Washington Department of Natural Resources. The ... in developing fire control strategies and tactics. Other cooperators ... of Natural Resources, (WA DNR), Bureau of Land Management, ...
(Date:7/11/2014)... scientists have set a "mouse TRAP" to capture the ... recent study published in the Journal of Clinical ... technique called TRAP to extract cellular and genetic information ... scientists at the Rockefeller Institute for Medical Research in ... protein-making machinery, or ribosomes, of the cell type of ...
Breaking Biology News(10 mins):Antibody halts cancer-related wasting condition 2Antibody halts cancer-related wasting condition 3
... River in Washington, D.C. is showing multiple benefits from ... improved water clarity have increased the abundance and diversity ... to direct measurements taken during the 18-year field study. ... the lower Potomac has doubled, the area covered by ...
... YORK, Sept. 7 Reportlinker.com announces that a new ... Biomarkers - technologies,markets and companies ... This report follows the broad definition of ... measured and evaluated as an indicator of normal biological ...
... 2009, newly installed photovoltaic (PV) cells world-wide produced a peak ... 5.8 GW was located in Europe. Similarly to previous years, ... of the world,s new solar systems were installed. By the ... (existing and newly installed) was 16 GW, which is about ...
Cached Biology News:Potomac River: 10-fold increase in native submerged vegetation reflects improved water quality 2Reportlinker Adds Biomarkers - technologies, markets and companies 2Reportlinker Adds Biomarkers - technologies, markets and companies 3Reportlinker Adds Biomarkers - technologies, markets and companies 4Reportlinker Adds Biomarkers - technologies, markets and companies 5Reportlinker Adds Biomarkers - technologies, markets and companies 6Reportlinker Adds Biomarkers - technologies, markets and companies 7Reportlinker Adds Biomarkers - technologies, markets and companies 8Reportlinker Adds Biomarkers - technologies, markets and companies 9Reportlinker Adds Biomarkers - technologies, markets and companies 10Reportlinker Adds Biomarkers - technologies, markets and companies 11Reportlinker Adds Biomarkers - technologies, markets and companies 12Reportlinker Adds Biomarkers - technologies, markets and companies 13Reportlinker Adds Biomarkers - technologies, markets and companies 14Reportlinker Adds Biomarkers - technologies, markets and companies 15Reportlinker Adds Biomarkers - technologies, markets and companies 16Reportlinker Adds Biomarkers - technologies, markets and companies 17Reportlinker Adds Biomarkers - technologies, markets and companies 18Reportlinker Adds Biomarkers - technologies, markets and companies 19Reportlinker Adds Biomarkers - technologies, markets and companies 20Three-quarters of new solar systems worldwide were installed in the EU in 2009 2Three-quarters of new solar systems worldwide were installed in the EU in 2009 3
BI-1 Polyclonal Antibody Storage Temperature: -20C Shipping: gel pack Shelf-Life: 12 months...
... cells of embryonal carcinoma of testis and ovary ... like seminoma. Glandular epithelium of yolk sac tumor ... cells of stomach and acini cells of pancreas ... Epitope: Carbohydrate portion on human embryonal carcinoma ...
... Endothelin-1 (human, porcine) Endogenous potent ... ETA receptor and modulates vascular tonus. ET-1, ... three distinct endothelin genes. ET-2 and ET-3 ... two and six amino acids, respectively. All ...
HP 1 alpha Immunogen: Synthetic peptide between amino acids 1-100 of the human HP 1 alpha protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: